IPMN explained — the commonest pancreatic cyst, and why most are low-risk

IPMN stands for intraductal papillary mucinous neoplasm — a mouthful of a name that is worth unpacking, because each part tells you something useful. Intraductal means it grows within the duct system of the pancreas. Papillary describes its finger-like growth pattern under the microscope. Mucinous means the cells produce mucin, a thick, gel-like fluid. Neoplasm simply means a new growth of tissue — a broader and less alarming word than “tumour,” which it is often mistakenly translated as.

Put together: IPMN is a growth within the pancreatic duct system that produces mucin, which is what makes the affected part of the duct swell into what looks, on a scan, like a cyst. It is by a wide margin the commonest type of pancreatic cyst found incidentally on scans done for unrelated reasons, and this frequency is itself part of why it is so well studied and so well understood, with detailed, structured guidance for managing it.

The single most important thing to know about IPMN is that it exists on a spectrum. At one end, most IPMNs are entirely low-risk and can be safely watched indefinitely. At the other, a minority can, over years, develop worrying features that raise the question of whether cancer is developing within them — which is exactly why structured, ongoing surveillance, rather than a one-off scan, is the standard approach. For the type-vs-type overview, see pancreatic cyst vs cancer — what a cyst really means.

1. 1

   Full characterisation on MRI/MRCP

   This maps exactly which part of the duct system is involved, the size, and whether any solid or nodular components are present — the details that set the entire monitoring plan.

   In-house at CION
2. 2

   Checking against worrisome-feature criteria

   A defined, published set of imaging and clinical features determines the level of concern and the recommended interval for follow-up.

   In-house at CION
3. 3

   Scheduled repeat imaging

   Most IPMNs are followed with MRI at defined intervals, comparing each scan carefully against the last for any change in size or the appearance of new features. See how pancreatic cysts are monitored.

   In-house at CION
4. 4

   Endoscopic ultrasound, if a closer look is needed

   Where imaging raises a genuine question, an endoscopic ultrasound gives closer detail, sometimes alongside sampling fluid from within the cyst itself for further testing.

   Coordinated with specialist endoscopy partners
5. 5

   Surgery, only where features genuinely warrant it

   The minority of IPMNs that develop clear worrisome features, or that involve the main duct significantly, may be removed. This is never a first response to the diagnosis itself.

   Coordinated with specialist HPB surgery partners

Most people with an IPMN feel completely well and have no symptoms related to it at all — that is precisely how the great majority are found, incidentally, on a scan done for something else entirely. There is generally no need to change your diet, activity or daily life because of an IPMN diagnosis alone.

What matters most practically is keeping to the surveillance schedule, even once the initial anxiety of the diagnosis fades and it starts to feel like “nothing is happening.” That apparent nothing is exactly the point — a stable, unchanged IPMN over successive scans is a genuinely reassuring result, not a wasted appointment. If your circumstances change — new symptoms, a new family history of pancreatic cancer, or simply moving cities — it is worth flagging that at your next review, since it can occasionally affect the recommended interval.

For the minority of IPMNs where surgery is genuinely warranted, the extent of the operation depends on where in the pancreas the IPMN sits and how much of the duct is involved — ranging from removing only the affected portion of the gland to a more extensive operation where the main duct is significantly involved throughout. This is coordinated with our specialist HPB surgery partners, and the decision is made collaboratively at our tumour board rather than by a single opinion.

If an IPMN is found, on tissue examination after surgery, to have already progressed towards or become cancer, the treatment approach follows the same framework as any pancreatic cancer diagnosis, set out on pancreatic cancer treatment in Hyderabad. This outcome is uncommon, and the entire point of structured surveillance is to catch any concerning change well before that point is reached.

Medical disclaimer: This page explains what an IPMN diagnosis means and how it is generally monitored, and is reviewed by a CION medical oncologist with reference to NCCN and international consensus guidance on IPMN. It is general information, not a diagnosis or a substitute for individual review of your own imaging. Most IPMNs are low-risk and safely monitored rather than treated. Blood tests, CA 19-9, contrast CT, MRI/MRCP, medical oncology, genetic counselling and nutrition support are delivered by CION; endoscopic ultrasound and biopsy, and any pancreatic surgery for cyst removal, are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.